Article
Author(s):
Washington-As Congress moves toward possible approval of a new prescriptiondrug program for Medicare recipients later this summer, determination ofpayments for cancer drugs and therapeutic services may well hang in thebalance.
Clarifying CPT 52353 billing for same-side stone cases
Health policy in urology: 2024 AUA Advocacy Summit recap
Cutting drug costs for patients: key takeaways for urologists
How APPs can bridge the gap in urologist shortages
How to bill for telephone-only urology visits
Level of service for vasectomy prompts coding confusion
Adjuvant pembrolizumab continues to show DFS, OS benefits for ccRCC at 5-year assessment
EFS benefit is seen with sasanlimab in CIS and T1 NMIBC
Perioperative sacituzumab govitecan/pembro yields compelling CR rate in MIBC
Interim ENLIGHTED data show promise for padeliporfin VTP therapy in UTUC